JP2002506008A - 血管新生を調整するための組成物及び方法 - Google Patents

血管新生を調整するための組成物及び方法

Info

Publication number
JP2002506008A
JP2002506008A JP2000535201A JP2000535201A JP2002506008A JP 2002506008 A JP2002506008 A JP 2002506008A JP 2000535201 A JP2000535201 A JP 2000535201A JP 2000535201 A JP2000535201 A JP 2000535201A JP 2002506008 A JP2002506008 A JP 2002506008A
Authority
JP
Japan
Prior art keywords
epc
mammal
csf
vascular
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000535201A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002506008A5 (fr
Inventor
ジェフリー エム． イスネル
孝之 浅原
Original Assignee
セント エリザベス メディカル センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セント エリザベス メディカル センター filed Critical セント エリザベス メディカル センター
Publication of JP2002506008A publication Critical patent/JP2002506008A/ja
Publication of JP2002506008A5 publication Critical patent/JP2002506008A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000535201A 1998-03-09 1999-03-09 血管新生を調整するための組成物及び方法 Withdrawn JP2002506008A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7726298P 1998-03-09 1998-03-09
US60/077,262 1998-03-09
PCT/US1999/005130 WO1999045775A1 (fr) 1998-03-09 1999-03-09 Compositions et methodes modulant la vascularisation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010157554A Division JP2010265301A (ja) 1998-03-09 2010-07-12 血管新生を調整するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2002506008A true JP2002506008A (ja) 2002-02-26
JP2002506008A5 JP2002506008A5 (fr) 2006-01-05

Family

ID=22137044

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000535201A Withdrawn JP2002506008A (ja) 1998-03-09 1999-03-09 血管新生を調整するための組成物及び方法
JP2010157554A Pending JP2010265301A (ja) 1998-03-09 2010-07-12 血管新生を調整するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010157554A Pending JP2010265301A (ja) 1998-03-09 2010-07-12 血管新生を調整するための組成物及び方法

Country Status (5)

Country Link
EP (1) EP1061800A4 (fr)
JP (2) JP2002506008A (fr)
AU (1) AU766238B2 (fr)
CA (1) CA2322559C (fr)
WO (1) WO1999045775A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005534651A (ja) * 2002-06-05 2005-11-17 ニューヨーク メディカル カレッジ 損傷心筋の修復及び／又は再生のための方法及び組成物
JP2005539031A (ja) * 2002-08-16 2005-12-22 シエーリング アクチエンゲゼルシャフト 野生型または変異型ｅＮＯＳによる重症肢虚血の遺伝子療法
WO2006030887A1 (fr) * 2004-09-17 2006-03-23 Cellgentech, Inc. Preparation externe pour le traitement des ulceres cutanes
JPWO2004054604A1 (ja) * 2002-12-13 2006-04-20 久義 藤原 非虚血性心不全治療用医薬組成物
WO2006075587A1 (fr) * 2005-01-11 2006-07-20 National University Corporation Nagoya University Remede compose de csf administre a faible dose
WO2006093172A1 (fr) * 2005-02-28 2006-09-08 Foundation For Biomedical Research And Innovation Procédé d’amplification in vitro de cellules souches adultes
JP2007535389A (ja) * 2004-04-30 2007-12-06 オーバスネイク メディカル インコーポレーテッド 遺伝子的に改変された細胞を捕捉する被覆を備えた医療デバイスおよびその使用方法
KR101336386B1 (ko) * 2011-06-17 2013-12-04 전북대학교병원 림프관 생성 유도제
JP2016155804A (ja) * 2002-04-23 2016-09-01 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 新血管新生の誘導による内因性の心筋組織の再生
WO2016147675A1 (fr) * 2015-03-18 2016-09-22 公益財団法人先端医療振興財団 Médicament pour le traitement et/ou la prévention de maladies ischémiques, procédé d'amélioration de l'activité stimulant l'angiogenèse de cellules, ou procédé de fabrication de médicament

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001094420A1 (fr) 2000-06-05 2001-12-13 The Trustees Of Columbia University In The City Of New York Identification et utilisation des cellules progenitrices endotheliales derivees de la moelle osseuse, destinees a ameliorer la fonction du myocarde apres un accident ischemique
IL153115A0 (en) * 2000-06-16 2003-06-24 Curis Inc Angiogenesis-modulating compositions and uses
AU2001284695A1 (en) 2000-07-31 2002-02-13 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
US7862810B2 (en) 2000-07-31 2011-01-04 New York Medical College Methods and compositions for the repair and/or regeneration of damaged myocardium
WO2002022163A1 (fr) 2000-09-13 2002-03-21 Chugai Seiyaku Kabushiki Kaisha Remedes contre des maladies ischemiques
AU2002227425B2 (en) * 2000-10-30 2005-10-20 Children's Medical Center Corporation Tissue-engineered vascular structures
CA2467557A1 (fr) * 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Agent mobilisant les cellules souches multipotentes d'un tissu dans le sang peripherique
WO2003059375A1 (fr) * 2002-01-17 2003-07-24 Cardio Incorporated Therapie complexe pour la regeneration des tissus
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
AU2008200822A1 (en) * 2002-08-22 2008-03-13 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
CN100366257C (zh) * 2002-08-22 2008-02-06 克里夫兰诊所基金会 基质细胞衍生因子-1介导缺血性心肌病中干细胞归巢及组织再生
US20040037811A1 (en) * 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors
ES2520044T3 (es) 2007-03-30 2014-11-11 The Cleveland Clinic Foundation SDF-1 para su uso en el tratamiento de trastornos vasculares periféricos isquémicos
WO2009062143A2 (fr) 2007-11-09 2009-05-14 New York Medical College Procédés et compositions pour la réparation et/ou la régénération de myocarde endommagé mettant en œuvre des cytokines et leurs variants
WO2009073616A2 (fr) 2007-11-30 2009-06-11 New York Medical College Compositions comprenant des cellules progénitrices vasculaires et myocytaires et procédés permettant de les utiliser
WO2009073594A1 (fr) 2007-11-30 2009-06-11 New York Medical College Procédés permettant de réduire le rejet de greffon et l'artériosclérose accélérée du greffon cardiaque par implantation de cellules souches autologues
US8512696B2 (en) 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009079451A2 (fr) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions et procédés pour favoriser la guérison d'une plaie
RU2470995C2 (ru) 2008-04-09 2012-12-27 Вайромед Ко., Лтд. Лиофилизированные днк-составы для увеличенной экспрессии плазмидной днк
JP5856059B2 (ja) 2009-08-28 2016-02-09 ザ クリーブランド クリニック ファウンデーション 虚血組織を治療するためのｓｄｆ−１送達
WO2012148200A2 (fr) * 2011-04-26 2012-11-01 아주대학교 산학협력단 Composition pour faciliter des procédures chirurgicales pour traiter des maladies vasculaires ischémiques
KR101609690B1 (ko) * 2011-04-26 2016-04-06 아주대학교산학협력단 허혈성 혈관 질환 치료시술 보조용 조성물
MX2016005006A (es) 2013-10-22 2016-07-14 Viromed Co Ltd Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito.
KR20210027493A (ko) 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808042A (en) * 1982-06-11 1989-02-28 Electro-Plasma, Inc. Powder feeder
US4879282A (en) * 1987-03-17 1989-11-07 Saliba Jr Michael J Medical application for heparin and related molecules
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US5880090A (en) * 1997-09-19 1999-03-09 The Hope Heart Institute Treatment of vascular graft implants with G-CSF

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016155804A (ja) * 2002-04-23 2016-09-01 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 新血管新生の誘導による内因性の心筋組織の再生
JP2010195804A (ja) * 2002-06-05 2010-09-09 New York Medical College 損傷心筋の修復及び／又は再生のための方法及び組成物
JP2005534651A (ja) * 2002-06-05 2005-11-17 ニューヨーク メディカル カレッジ 損傷心筋の修復及び／又は再生のための方法及び組成物
JP4685445B2 (ja) * 2002-06-05 2011-05-18 ニューヨーク メディカル カレッジ 損傷心筋の修復及び／又は再生のための方法及び組成物
JP2005539031A (ja) * 2002-08-16 2005-12-22 シエーリング アクチエンゲゼルシャフト 野生型または変異型ｅＮＯＳによる重症肢虚血の遺伝子療法
JPWO2004054604A1 (ja) * 2002-12-13 2006-04-20 久義 藤原 非虚血性心不全治療用医薬組成物
JP2007535389A (ja) * 2004-04-30 2007-12-06 オーバスネイク メディカル インコーポレーテッド 遺伝子的に改変された細胞を捕捉する被覆を備えた医療デバイスおよびその使用方法
JPWO2006030887A1 (ja) * 2004-09-17 2008-05-15 セルジェンテック株式会社 外用皮膚潰瘍治療剤
WO2006030887A1 (fr) * 2004-09-17 2006-03-23 Cellgentech, Inc. Preparation externe pour le traitement des ulceres cutanes
WO2006075587A1 (fr) * 2005-01-11 2006-07-20 National University Corporation Nagoya University Remede compose de csf administre a faible dose
WO2006093172A1 (fr) * 2005-02-28 2006-09-08 Foundation For Biomedical Research And Innovation Procédé d’amplification in vitro de cellules souches adultes
KR101336386B1 (ko) * 2011-06-17 2013-12-04 전북대학교병원 림프관 생성 유도제
WO2016147675A1 (fr) * 2015-03-18 2016-09-22 公益財団法人先端医療振興財団 Médicament pour le traitement et/ou la prévention de maladies ischémiques, procédé d'amélioration de l'activité stimulant l'angiogenèse de cellules, ou procédé de fabrication de médicament
US11744858B2 (en) 2015-03-18 2023-09-05 Foundation For Biomedical Research And Innovation At Kobe Medicine for treatment and/or prevention of ischemic diseases, method for improving angiogenesis-promoting activity of cells, or method for producing medicine

Also Published As

Publication number Publication date
EP1061800A4 (fr) 2004-10-06
WO1999045775A1 (fr) 1999-09-16
AU766238B2 (en) 2003-10-09
CA2322559C (fr) 2012-07-17
CA2322559A1 (fr) 1999-09-16
EP1061800A1 (fr) 2000-12-27
JP2010265301A (ja) 2010-11-25
AU3073799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
AU766238B2 (en) Compositions and methods for modulating vascularization
US6676937B1 (en) Compositions and methods for modulating vascularization
Ohki et al. Granulocyte colony‐stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils
Miller-Kasprzak et al. Endothelial progenitor cells as a new agent contributing to vascular repair
JP4672370B2 (ja) 虚血の細胞ベースの治療
Ballard et al. Vascular tenascin‐C regulates cardiac endothelial phenotype and neovascularization
Murasawa et al. Endothelial progenitor cells for vasculogenesis
US8119398B2 (en) Adipose-derived stem cells for tissue regeneration and wound healing
Hiasa et al. Bone marrow mononuclear cell therapy limits myocardial infarct size through vascular endothelial growth factor
US9095580B2 (en) Compositions and methods for regulating angiogenesis
US20060003932A1 (en) Method for promoting neovascularization
Liu et al. Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction
JP2005007196A (ja) ヒト・骨形態形成蛋白を用いる神経再生
JP2008504290A (ja) 虚血の細胞ベースの治療
JP2004043507A (ja) 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
Zhou et al. G‐CSF‐mobilized peripheral blood mononuclear cells from diabetic patients augment neovascularization in ischemic limbs but with impaired capability
WO2008107422A1 (fr) Ostéopontine destinée à la prédiction et au traitement de maladies cardiovasculaires
Gentile et al. Ultrastructural and Immunohistochemlcal Characterization of the Tunica Albuginea in Peyronie's Disease and Veno‐occlusive Dysfunction
R Hollander et al. Cellular and pharmacological targets to induce coronary arteriogenesis
WO2000062798A2 (fr) Facteurs de croissance angiogenique destines au traitement de neuropathie peripherique
US20040228834A1 (en) Compositions and methods for modulating vascularization
Jeon et al. Synergistic effect of sustained delivery of basic fibroblast growth factor and bone marrow mononuclear cell transplantation on angiogenesis in mouse ischemic limbs
Padilla et al. Bone marrow mononuclear cells stimulate angiogenesis when transplanted into surgically induced fibrocollagenous tunnels: results from a canine ischemic hindlimb model
US20230034582A1 (en) Cell population and method of obtaining the same
Risser Modulating Macrophage Phenotype for the Promotion of Angiogenesis in an Ischemic Environment

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051012

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051012

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20081007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090421

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090428

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090810

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091106

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091113

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100310

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100712

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100712

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100817